Skin starts to heal quickly
*Skin condition scores assessed by veterinarians using the CADESI-03 score.
Skin condition assessed by veterinarians using the Canine Atopic Dermatitis Extent and Severity Index (CADESI-03) score.
Indication: CYTOPOINT treats clinical manifestations of atopic dermatitis in dogs.
References: 1. Data on file, Study Report No. C866C-XC-13-056, Zoetis Inc. 2. Data on file, Study Report No. C866C-XC-14-082, Zoetis Inc.
The material contained within this website is intended to be viewed by practising veterinary surgeons in the UK only. The drugs listed in this website may have different technical specifications approved in other countries.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
© 2017 Zoetis Services LLC. All rights reserved. MM-01580
Skin starts to heal quickly
Skin condition scores assessed by veterinarians using the CADESI-03 score.
Skin condition assessed by veterinarians using the Canine Atopic Dermatitis Extent and Severity Index (CADESI-03) score.
Indication: CYTOPOINT treats clinical manifestations of atopic dermatitis in dogs.
References: 1. Data on file, Study Report No. C866C-XC-13-056, Zoetis Inc. 2. Data on file, Study Report No. C866C-XC-14-082, Zoetis Inc.
The material contained within this website is intended to be viewed by practicing veterinary surgeons in the UK only. The drugs listed in this website may have different technical specifications approved in other countries.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
© 2017 Zoetis Services LLC. All rights reserved. MM-01580
STUDY DESIGN
In a multicentre, double-blind field trial in four countries in Europe, 274 dogs were treated with either 3 monthly doses of CYTOPOINT® (using a dosing table that targeted a minimum dose of 1.0 mg/kg and actually delivered between 1.0-3.3 mg/kg based on the dog’s weight within the dose band) or Atopica® (cyclosporine) at label dose. To ensure that treatment was blinded, Atopica-treated dogs received monthly injections of saline and CYTOPOINT-treated dogs received daily placebo tablets.
Primary efficacy parameters were improvement in pruritus (based on percentage reduction from baseline in owner-assessed VAS) and skin lesions (based on percentage reduction in CADESI-03 as assessed by the veterinary dermatologist); these were assessed on the third study visit (Day 28 ±5).
In this extension trial lasting a maximum of 6 months, CYTOPOINT was administered to dogs that successfully completed the 3-month multicentre field trial (C866C-XC-13-056). As in the 3-month trial, CYTOPOINT continued to be administered subcutaneously every 28 days. Pruritus continued to be evaluated based on owner-assessed VAS, and skin lesions continued to be evaluated based on CADESI-03 scoring by the veterinary dermatologist.
- Argentina
- Australia
- Austria
- Belgium
- Bolivia
- Brazil
- Bulgaria
- Canada
- Chile
- China
- Colombia
- Costa Rica
- Croatia
- Czech Republic
- Denmark
- Ecuador
- Egypt
- Estonia
- Ethiopia
- Finland
- France
- Germany
- Ghana
- Greece
- Hungary
- India
- Indonesia
- Ireland
- Israel
- Italy
- Japan
- Kenya
- Latvia
- Liberia
- Lithuania
- Malawi
- Malaysia
- Mauritius
- Mexico
- Morocco
- Mozambique
- Netherlands
- New Zealand
- Nigeria
- Paraguay
- Peru
- Philippines
- Poland
- Portugal
- Romania
- Russia
- Serbia
- Singapore
- Slovakia
- Slovenia
- South Africa
- South Korea
- Spain
- Switzerland
- Taiwan
- Tanzania
- Thailand
- Turkey
- Uganda
- Ukraine
- United Kingdom
- United States
- Uruguay
- Vietnam
- Zambia
- Zimbabwe
You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.